Adagio Therapeutics Inc Stock
Adagio Therapeutics Inc Stock price
Key metrics
| Market capitalization | $94.42m |
| Enterprise Value | $-52.78m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | 0.28 |
| EV/Sales (TTM) EV/Sales | -23.35 |
| P/S ratio (TTM) P/S ratio | 41.78 |
| P/B ratio (TTM) P/B ratio | 0.67 |
| Revenue (TTM) Revenue | $11.56m |
| EBIT (operating result TTM) EBIT | $-235.00m |
Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
Adagio Therapeutics Inc Stock Analysis
Analyst Opinions
5 Analysts have issued a Adagio Therapeutics Inc forecast:
Analyst Opinions
5 Analysts have issued a Adagio Therapeutics Inc forecast:
Financial data from Adagio Therapeutics Inc
| Sep '24 |
+/-
%
|
||
| Revenue | 12 12 |
-
|
|
| Gross Profit | 8.56 8.56 |
598%
598%
|
|
| EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -235 -235 |
34%
34%
|
| Net Profit | -225 -225 |
33%
33%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.
| Head office | United States |
| CEO | William Duke |
| Employees | 94 |
| Founded | 2020 |
| Website | invivyd.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
